

FOR IMMEDIATE RELEASE

Apogee Investor Contact:
Paul Murphy
Apogee Technology, Inc.
781-551-9450
pmurphy@apogeemems.com

Apogee files Five U.S. Patent Applications for its PyraDerm™ Drug Delivery System

NORWOOD, Mass. (September 28, 2006) — Apogee Technology, Inc. (AMEX: ATA), an emerging micro-systems and nanotechnology company that designs, develops and commercializes medical devices and sensor products, announced today that it has filed five U.S. provisional patent applications related to its PyraDerm™ intradermal drug delivery system. Three of the new patent applications pursue the protection of methods and compositions for specific biomedical applications and two of the patent applications pertain to novel drug delivery formulations for biomedical devices and associated microfabrication processes.

Dr. Alexander K. Andrianov, Apogee's Vice President of Research & Development said, "This is a significant milestone in the development of our intellectual property position. These new filings expand the portfolio of patents and patent applications related to our micro needle drug delivery technology. We are now focusing our development resources on the in vivo validation of this technology and its introduction to strategic partners."

About Apogee Technology, Inc.

Apogee Technology designs, develops and commercializes proprietary medical device and sensor products using its MEMS and nanotechnology for the medical, automotive, industrial and consumer markets. The Company is developing its PyraDerm™ solution for enhanced intradermal drug delivery and has introduced a family of pressure sensors under the Sensilica™ brand. Apogee's goal is to provide value-added and cost-savings solutions for our customers and, in so doing, to become a global leader in the sensor and medical device fields. For more information please visit our web site at: <http://www.apogeemems.com>.

##

PyraDerm™ and Sensilica™ are trademarks of Apogee Technology, Inc. All other product names noted herein may be trademarks of their respective holders. Certain statements made herein that use the words "anticipate,"

"hope," "estimate," "project," "intend," "plan," "expect," "believe" and similar expressions are intended to identify forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve known and unknown risks and uncertainties, which could cause the actual results, performance or achievements of the Company to be materially different from those that may be expressed or implied. Please refer to the company's risk factors as set forth in the Company's filings with the Securities and Exchange Commission, including its reports on Forms 10-KSB and 10-QSB.